This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)
Issued: Wednesday 23 June 2010, London UK
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a variation to the conditional marketing authorisation for Tyverb® (lapatinib) in the European Union for a new therapeutic indication. Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
|
GlaxoSmithKline Enquiries:
|
|
|
|
UK Media enquiries:
|
Philip Thomson
|
(020) 8047 5502
|
|
|
Claire Brough
|
(020) 8047 5502
|
|
|
Stephen Rea
|
(020) 8047 5502
|
|
|
Alexandra Harrison
|
(020) 8047 5502
|
|
|
Jo Revill
|
(020) 8047 5502
|
|
|
|
|
|
European Analyst/Investor enquiries:
|
David Mawdsley
|
(020) 8047 5564
|
|
|
Sally Ferguson
|
(020) 8047 5543
|
|
|
Gary Davies
|
(020) 8047 5503
|
Subscribe to press releases
Printer-friendly version
Send by email